- Price is above Fair Value, showing premium demand versus the model.
- Latest weekly return ranks in the strongest part of its sector group.
9637
HKG
Week ended 07 Aug 2026
Weekly Investor Report
Alebund Pharmaceuticals (Jiangsu) Limited · Healthcare · Drug Manufacturers - General
Latest close
32.68 HKD
20.0%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is - below the Trend Line and sits at 84.4% of its 52-week range. The latest completed week returned 20.0%, after a 5.6% four-week move. The latest news-sentiment score is 52/100.
Setup score
38
out of 100
Latest Close
32.68 HKD
7 Aug 2026
1W Return
20.0%
latest completed week
4W Return
5.6%
short-term follow-through
12W Return
-
quarterly tape
Trend Breadth
0.0%
0 of 6 weeks active
Volume Ratio
1.0x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is negative, which weakens the current setup.
- Next-week expectancy is negative at 43.14% based on similar historical setup states.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
20.0%
Latest completed week; four-week move 5.6%.
Indicator stack
0/50
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 43.14%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
52/100
9 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is - below the Trend Line and sits at 84.4% of its 52-week range. The latest completed week returned 20.0%, after a 5.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2012-week average 0.20
12-week confirmation
Trend active0/6Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/6Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/6Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.20Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 5.6% over four weeks, - over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.00Latest activity-pressure read.
Pressure change-Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment52/100
Weighted news tone is neutral across 9 relevant articles.
2 positive · 6 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-3.7%Distance below the 52-week high.
13-week volatility10.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
3 Jul
7 Aug
Weeks higher3 of 52 weeks finished lower.
Best week+20.0%Week of 7 Aug.
Worst week-9.7%Week of 17 Jul.
Latest week+20.0%Week of 7 Aug.
Shape of recent returns
Strong gains1
Modest gains2
Flat weeks0
Modest losses0
Sharp losses2
Recent vol10.2%13-week weekly-return volatility.
Base vol10.2%52-week weekly-return volatility.
Up/down split3/2Count of positive and negative weeks in the 52-week window.
Average skew8.5% / -7.7%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorHK Healthcare
4-week rank30 / 100
Group average4.4%
Trend breadth12.0%
Trend12.0%active weekly trend signals
MD32.0%positive activity pressure
RS19.0%positive relative leadership
Four-week leaders
IndustryHK Drug Manufacturers - General
4-week rank4 / 7
Group average28.5%
Trend breadth0.0%
Trend0.0%active weekly trend signals
MD28.6%positive activity pressure
RS0.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape33/100
Trend, activity pressure, participation, and risk combine to a 33/100 tape read.
Indicator analysis8/100Latest 12-week confirmation: trend 0/6, activity pressure 0/6, relative leadership 0/6.
Activity pressure 0.20; 2 reversal markers Next-Week ExpectancyNegative 43.14%Next-week expectancy is negative with a 43.14% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment52/100Weighted news tone is neutral across 9 relevant articles.
Alebund’s AP301 NDA Accepted in China After Strong Phase III Dialysis Data Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 32.68 HKD | 20.0% | - | 29.67 HKD | 0.00 | - | 1.9M | Off |
| 31 Jul 2026 | 27.24 HKD | -5.8% | - | 29.07 HKD | 0.00 | - | 1.1M | Off |
| 24 Jul 2026 | 28.92 HKD | 3.4% | - | 29.53 HKD | 0.00 | - | 850.2K | Off |
| 17 Jul 2026 | 27.96 HKD | -9.7% | - | 29.73 HKD | - | - | 2.7M | Off |
| 10 Jul 2026 | 30.96 HKD | 2.2% | - | 30.62 HKD | - | - | 3.1M | Off |
| 3 Jul 2026 | 30.28 HKD | - | - | 30.28 HKD | - | - | 1.3M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.